[{"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 399 9500", "website": "https://www.tscan.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 154, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gavin  MacBeath Ph.D.", "age": 53, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 650173, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen J. Elledge Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tomasz  Kula Ph.D.", "title": "Co-Founder & Member of Advisory Board", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason A. Amello", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Leiden  Dworak M.B.A.", "title": "Principal Accounting Officer & Treasurer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Justin  McCue Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zoran  Zdraveski J.D., Ph.D.", "age": 52, "title": "Chief Legal & Strategy Officer and Company Secretary", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann  Hargraves", "title": "Senior Vice President of Human Resources", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shrikanta  Chattopadhyay M.D.", "title": "Senior VP & Head of Translational Medicine", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Debora  Barton M.D.", "age": 47, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.94, "open": 8.03, "dayLow": 7.72, "dayHigh": 8.155, "regularMarketPreviousClose": 7.94, "regularMarketOpen": 8.03, "regularMarketDayLow": 7.72, "regularMarketDayHigh": 8.155, "beta": 0.862, "forwardPE": -7.2162166, "volume": 121398, "regularMarketVolume": 121398, "averageVolume": 174300, "averageVolume10days": 303468, "averageDailyVolume10Day": 303468, "marketCap": 383536448, "fiftyTwoWeekLow": 1.62, "fiftyTwoWeekHigh": 9.0, "priceToSalesTrailing12Months": 18.221125, "fiftyDayAverage": 6.5244, "twoHundredDayAverage": 4.3981, "currency": "USD", "enterpriseValue": 283925376, "floatShares": 21099768, "sharesOutstanding": 43605600, "sharesShort": 188336, "sharesShortPriorMonth": 252940, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.0039, "heldPercentInsiders": 0.00887, "heldPercentInstitutions": 0.83119005, "shortRatio": 0.98, "shortPercentOfFloat": 0.0049, "impliedSharesOutstanding": 5143130, "bookValue": 3.154, "priceToBook": 2.5396323, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -89218000, "trailingEps": -1.36, "forwardEps": -1.11, "enterpriseToRevenue": 13.489, "enterpriseToEbitda": -3.223, "52WeekChange": 2.6409092, "SandP52WeekChange": 0.28136122, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "TCRX", "underlyingSymbol": "TCRX", "shortName": "TScan Therapeutics, Inc.", "longName": "TScan Therapeutics, Inc.", "firstTradeDateEpochUtc": 1626442200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "78cfed2a-5d5f-3a28-9bf2-d5f7bc0c36ba", "messageBoardId": "finmb_583057578", "gmtOffSetMilliseconds": -14400000, "currentPrice": 8.01, "targetHighPrice": 15.0, "targetLowPrice": 9.0, "targetMeanPrice": 11.6, "targetMedianPrice": 10.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 192044000, "totalCashPerShare": 4.011, "ebitda": -88097000, "totalDebt": 92433000, "quickRatio": 6.44, "currentRatio": 6.514, "totalRevenue": 21049000, "debtToEquity": 61.268, "revenuePerShare": 0.321, "returnOnAssets": -0.24790001, "returnOnEquity": -0.71289, "freeCashflow": -41827624, "operatingCashflow": -61358000, "revenueGrowth": 1.33, "operatingMargins": -2.96173, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-02"}]